Biolexis to collaborate with Akston Biosciences for COVID-19 vaccine

Biolexis, a division of Stelis Biopharma, and Akston Biosciences have inked a licensing, manufacturing and commercialisation agreement regarding a COVID-19 vaccine.

In a joint statement, the two companies said they will collaborate for the production and sales of Akston’s AKS-452, a protein subunit COVID-19 vaccine.

Under the agreement, Biolexis gained the right to manufacture and commercialise AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa, largely covering the low-and middle-income countries (LMICs).

Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships.